Case analysis of linezolid in treatment of hospital-acquired MRSA pneumonia after ineffective glycopeptide antibiotics treatment
10.3969/j.issn.1671-8348.2017.33.020
- VernacularTitle:利奈唑胺治疗糖肽类抗菌药物无效的医院获得性MRSA肺炎的病例分析
- Author:
Rui LONG
1
;
Feng QIU
;
Long MENG
;
Jiadan YANG
;
Chengzhi ZHANG
Author Information
1. 重庆医科大学附属第一医院药学部 400016
- Keywords:
methicillin-resistant staphylococcus aureus;
hospital-acquired pneumonia;
linezolid;
glucopeptide antibacterial drugs
- From:
Chongqing Medicine
2017;46(33):4664-4666
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the case of inezolid in effectively treating hospital-acquired methicillin-resistant staphylo-coccus aureus (MRSA) pneumonia after ineffective glycopeptide antibiotics treatment in order to provide opinions for the clinical use .Methods The antibacterial drugs analysis was performed on 1 case of hospital-acquired MRSA pneumonia after acute subdural hematoma removal operation in this hospital ,and the curative effects and economic indicators of glycopeptide antibacterial drugs and inezolid were conducted the evidence-based evaluation .Results Using glycopeptide antibacterial drugs in this patient had poor cura-tive effect ,and then changing to inezolid anti-infection treatment obtained the success .This patient used vancomycin 2 g ,generic teicoplanin 400 mg and inezolid 1200 mg per day ;the average daily costs were 497 ,341 ,788 Yuan respectively .Conclusion Lin-ezolid can be selected for treating hospital-acquired MRSA pneumonia patient after ineffective glycopeptide antibacterial drugs treat-ment .
